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Summary 
Interleukin 15 (IL-15) is a novel cytokine that has recently been doned and expressed. Whereas 
it has no sequence homology with IL-2, IL-15 interacts with components of the IL-2 receptor 
(IL-2R).  In the present study we performed a functional analysis of recombinant IL-15  on 
phenotypically and functionally distinct popttlations of highly purified human natural killer (NK) 
cells. The CD56  b~ht subset of human NK cells constitutively expresses the high affinity IL-2R 
and exhibits a brisk proliferative response after the binding of picomolar amounts of IL-2. Using 
a proliferation assay, IL-15 demonstrated a very steep dose-response curve that was distinct from 
the dose-response curve for IL-2. The proliferative effects of IL-15 could be abrogated by anti- 
IL-2R~ (p75), but not by anti-IL-2Rc~  (p55).  The proliferative  effects of IL-2 on CD56bns  ht 
NK cells could be inhibited by both antibodies.  CD56  ~n NK cells express the intermediate 
affinity  IL-2R in the absence of the high affinity  IL-2R. Activation of CD56  a~ NK cells by 
IL-15 was similar to that of IL-2 as measured by enhanced NK cytotoxic activity,  antibody- 
dependent cdlular cytotoxicity, and NK cell production of interferon %  tumor necrosis factor 
c~, and granulocyte/macrophage colony-stimulating factor. The IL-15-enhanced NK cytotoxic 
activity could be completely blocked by anti-IL-21L8  monoclonal antibody. The binding of 
radiolabded IL-2 and IL-15 to CD56  d~n NK cells was inhibited in the presence of anti-IL-21LB. 
Scatchard analysis of radiolabeled  IL-15 and IL-2 binding to NK-enriched human lymphocytes 
revealed the presence of high and intermediate affinity receptors for both ligands. IL-15 is a ligand 
that activates human NK cells through components of the IL-2R in a pattern that is similar 
but not identical to that of IL-2. Unlike IL-2, IL-15 is produced by activated monocytes/macro- 
phages. The discovery of IL-15 may increase our understanding of how monocytes/macrophages 
participate in the regulation of NK cell function. 
H 
uman NK cells are LGL that do not rearrange TCR 
genes, and demonstrate cytotoxic activity against tumor 
and viraUy infected cell targets without prior sensitization 
or MHC restriction. As such, NK cells appear  to have an 
important role in the early defense against viral infection and 
malignant transformation (for a review see reference  1). 
NK cells can be identified phenotypically by the expres- 
sion of CD56, an isoform of the human neural cell adhesion 
molecule, as well as CD16 or FcR3,III (1). Approximately 
10%  of NK cells have high density expression of CD56 
(CD56b~isht). The CD56br~  ht NK cells constitutively express 
the high affinity heterotrimeric IL-2 receptor (IL-2RoeB'y), 
as well as the intermediate affinity heterodimeric IL-2RB3; 
(2, 3). The more abundant CD56  di~ NK cells constitutively 
express the intermediate affinity heterodimeric IL-2RB3' (4). 
IL-2  binding  to  the  high  affinity  IL-2R  expressed  on 
CD56b~g  ht NK cells results in a strong proliferative response, 
whereas complete saturation of the intermediate affinity IL- 
2R on either CD56b~i#  t or CD56  aim NK cells results in en- 
hanced cytotoxic activity with little or no effect of prolifera- 
tion (2). Thus, NK cells appear  to have relatively  distinct 
functional responses  after  the binding of IL-2 to the high 
or intermediate affinity  IL-2R. 
IL-15 is a novel cytokine that has recently been cloned from 
the simian kidney epithelial cell line, CV1/EBNA (5). Whereas 
the sequence of IL-15 shows no homology with IL-2, IL-15 
can bind to a variety of cell lines, human mononuclear cells, 
and activated T cells. On activated T cells, IL-15 appears to 
1395  J. Exp.  Med. ￿9  The Rockefeller  University Press ￿9 0022-1007/94/10/1395/09  $2.00 
Volume  180  October 1994  1395-1403 use components of the IL-2tL for binding and signal trans- 
duction (5, 6). In contrast to IL-2, IL-15 appears to be much 
more abundantly expressed in a wide variety of tissues, in- 
chding phcenta, skeletal muscle, kidney, and activated mono- 
cytes/macrophages (5). Thus, IL-15 may be very important 
for NK cell function as NK cells are unique among human 
lymphocytes in their constitutive expression of functional IL- 
2R.  We  therefore investigated  the  functional  response  of 
human NK ceUs to IL-15, and compared these responses to 
those of IL-2. 
Materials  and Methods 
Cytokines.  Purified, yeast-derived,  recombinant human IL-15 
was provided by Immunex Research and Development Corpora- 
tion. Purified rib2 was obtained from Hoffmann LaKoche (Nutley, 
NJ; sp act, 1.53  x  107 U/mg). Purified rIL-12 (sp act, 4.5  x  106 
U/rag) was obtained from Genetics Institute Inc. (Cambridge, MA). 
Recombinant human TNF-ot (sp act,  2  x  10  s U//~g) was  ob- 
tained from the Asahi Chemical Corporation (Fuji City, Japan). 
All cytokines were constituted in RPMI-1640 with 0.1% human 
albumin (Armour Pharmaceutical Co.,  Kankakee,  IL). 
mAbs.  The anti-p75 (anti-IL-2Rfl or anti-CD122) mAb (7) and 
the anti-p55  (anti-IL-2R.ot or anti-CD25) mAb (8) were kindly 
provided as ascites by Dr. Kendall Smith (Cornell Medical Sehool, 
New York). Antibody was purified from ascites using the Affi-gel 
protein A mAb purification system II kit (Bio-Rad Laboratories, 
Richmond, CA) in accordance with the manufacturer's instruc- 
tions. 3FSB11 is an anti-HLA-DR murine mAb that was purified 
in an identical fashion and was used as an isotype control (9). Anti- 
CD3 and CD4 sterile mouse ascites were a generous gift of Dr. 
Stuart Schlossman  (Dana Farber Cancer Institute, Boston, MA). 
PE-conjugated  anti-CD56 mAb (NKH1-RD1) was purchased from 
Coulter Immunology (Hialeah, FL). Polyclonal rabbit anti-mouse 
lymphocyte serum was  purchased from Accurate Chemical and 
Scientific Corp.  (Westbury, NY). 
CelILines.  Target cells for LAK activity and antibody-dependent 
cellular cytotoxicity (ADCC) ~, assays were COLO  205,  a NK- 
resistant  human colon adenocarcinoma cell line, and P815, a NK- 
resistant  murine mastocytoma cell line, respectively Cells  were 
grown in ILPMI-1640 supplemented with 10% heat-inactivated FCS 
(Sigma Chemical Co., St. Louis, MO), anti-PPLO agent, and anti- 
biotics (GIBCO BR.L, Gaithersburg, MD). 
Isolation of  Human NK Cells.  Mononuclear cells were obtained 
from fresh lenkopacs  (American Red Cross, Buffalo,  NY) using 
Ficoll-Hypaque density gradient centrifugation (Sigma Chemical 
Co.). Cells were then washed twice in RPMI-1640 supplemented 
with 10% human AB serum (HAB), and adhered to plastic  for 
2 h. T cells, B cells, and remaining monocytes were depleted using 
goat anti-mouse immunomagnetic beads (Advanced  Magnetics, 
Inc., Cambridge, MA), and a combination of murine mAb reac- 
tive against CD3,  CD4,  and HLA-DIL, as described (9).  Non- 
depleted cells were then stained with CD56-PE, washed in 10% 
HAB, and sorted for CD56  b~ht and CD56 ~m NK cells on a FAC- 
Star Plus |  (Becton Dickinson & Co., Mountain View, CA) (2). 
Sorted CD56 + NK cells were >97% pure by FACStar |  analysis. 
Proliferation Assays.  2  x  104 CD56bns  ht or CD56 a~ NK cells 
were plated in U-bottom plates in the presence or absence of IL-15 
or Ib2 and incubated at 37~  for 84 h. In blocking experiments, 
1  Abbreviations used in  this paper: ADCC,  antibody-dependent cellular 
cytotoxicity; HAB, human AB serum. 
ceils were preincubated with saturating concentrations of either 
anti-p55, anti-p75, or isotype nonreactive control mAb for 1 h be- 
fore the addition of cytokine. Proliferation was measured by methyl- 
[3H]thymidine incorporation during the last  12 h of incubation. 
Results represent the mean of triplicate wells  _+  SE and are ex- 
pressed  as counts per minute of [3H]thymidine incorporation. 
s~Chroraium-release Cytotoxicit2/Assay.  Sorted CD56  ~m NK cells 
were plated in 96-well V-bottom plates (Costar Corp., Cambridge, 
MA) in 200 ~1 of RPMI-1640 media supplemented with 10% HAB 
with or without cytokine. After an 18-h incubation at 37~  4  x 
103 SlCr-labeled COLO 205 tumor target cells were added to each 
well. Phtes were then centrifuged for 3 min at 800 rpm and in- 
cubated for an additional 4 h at 37~  Hates were then centrifuged 
and the supernatant from each well was harvested using a filter 
harvesting system (Skatron Inc., Sterling, VA). Minimum and max- 
imum release were determined in 10% HAB and 1% NP-40 deter- 
gent, respectively. Specific lysis was determined as previously de- 
scribed  (10).  ADCC  assays were performed against  P815  cells 
preincubated with  either medium  alone or a  1:100 dilution of 
polyclonal rabbit  anti-mouse  lymphocyte serum  as  previously 
described  (11). 
NK  Cell  Cytoleine Production.  l0  s sorted CD56 ~  NK ceils 
were plated in the presence or absence  of cytokines in 96-well 
U-bottom plates in a total volume of 200/~1 of per well. Medium 
consisted of ILPMI-1640 plus 10% HAB. Cells were then incubated 
at 37~  for 72 h, after which supernatants were harvested and as- 
sayed by ELISA for production of human TNF~, GM-CSF (Quan- 
tikine; R & D Systems, Minneapolis,  MN), and IFN-7 (GIBCO 
BILL). Results represent the mean of duplicate wells  _+  SE. 
Scatchard Analysis of  ILl5 Binding to Resting NK Cells.  Recom- 
binant simian IL-15 expressed in yeast and purified as described by 
Grabstein et al. (5) was radiohbded using immobilized lactoperox- 
idase (Enzymeobead reagent, Bio-Rad Laboratories) to sp act, 1.8 x 
101  s cpm/mmol. Initial protein concentration of IL-15 was deter- 
mined by amino add analysis and the bioactivity of the radiohbeled 
protein was measured in an IL-15-dependent CTLL-2 proliferation 
assay as described in further detail by Giri et al. (6). 
Binding experiments were carried out at 4~  for I h, with con- 
ditions empirically determined to result in saturable binding and 
reduced rate of internalization of lzsI-II~15 bound to cell surface 
receptors.  Binding experiments were performed using the phtha- 
late oil separation method and data analysis as described by Dower 
et al.  (12). In each experiment, between 5  ￿  107 and 1  x  104 
resting human NK cells were used. Resting human NK cells were 
purified by depleting nonadherent PBMC of T  cells and B cells 
with immunomagnetic purging as described above. Cells were be- 
tween  75  and  90%  CD3-CD56 + by FACS  |  analysis  (Becton 
Dickinson & Co.). In some experiments, depleted cells were again 
labeled  with  anti-CD3  mAb  and  subsequently  passed  over  a 
magnetic-activated cell sorter (MACS) column (Milentyi Biotec, 
Sunnyvale, CA), which brought the purity of CD3-CD56 + cells 
up to 90% by FACS  |  analysis. Freshly depleted resting NK cells 
were sent by overnight courier from Buffalo, NY to Seattle, WA 
on wet ice. Upon arrival,  Ib2 and IL-15 binding studies were car- 
fled out as described above. To confirm that overnight shipment 
had not led to artifactual findings,  reagents for isolation of NK 
cells were sent to Seattle on one occasion and binding studies were 
performed on freshly isolated NK cells with identical results. 
Results 
Effects of IL-15 on Human  NK  Cell Proliferation.  Initial 
studies with IL-15 had shown that it could stimulate lym- 
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proceeded to compare the proliferative  effects of IL-15  and 
IL-2 on highly purified NK cells that constitutively express 
the IL-2R. CD56b~ ht NK cells constitutively express a high 
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Figure  1.  Proliferation  of NK cell subsets in the presence of rIL-2 or rll_,15. (,4) CD56ba8  ht NK cells were sorted  from fresh PBL and cultured 
in medium plus varying concentrations  of IL-2 or II.r15 for 84 h and then assayed for methyl-[SH]thymidine  incorporation during the final 12 h of 
incubation.  Results represent  the mean  +  SE of triplicate  wells of a representative  e~periment.  (B) Identical  assay on sorted CD56  aim NK cells. (C) 
Proliferation  of CD56b~  ht NK ceils in the presence of varying concentrations  of IL-2 plus anti-IL-2Ro~ (antl-p55 mAb) or isotype control mAb. (D) 
Proliferation  of CD56b'ig  ht NK ceils in the presence of varying concentrations  of IL-15 plus anti-IIr2Rol or isotype control mAb. (E) Proliferation  of 
CD56b~  bt NK cells in the presence of varying concentrations  of IL-2 plus anti-IL-2I~ (anti-p75 mAh) or isotype control mAb. (b  0  Proliferation  of 
CD561"ig  ht NK cells in the presence of varying concentrations  of IL-15 plus anti-IL-2t~ or isotype control mAb. 
1397  Carson et al. high affinity IL-2R (i.e., 0.10 and 1.0 ng/ml). 10 ng/ml of 
IL-2 afforded full saturation  of the high affinity IL-2R and 
partial  saturation  of the intermediate affinity IL-2R,  and 
resulted in a maximal proliferative response. Further increases 
in the concentration of IL-2 to 100 ng/ml fully saturated the 
intermediate affinity  IL-2R  expressed on  CD56  b~ight NK 
cells, but did not increase proliferation  (2). 
In contrast to IL-2, IL-15 did not induce proliferation of 
CD56  bright NK cells at concentrations ranging from 0.01 to 
1.0 ng/ml in over 20 separate experiments. However, at 10 
ng/ml, IL-15 produced a maximal proliferative response in 
CD56b~g  ht  NK  ceils. Thus  IL-15 had  a  much  steeper 
dose-response curve than IL-2 (Fig. 1 A). Like IL-2, addi- 
tional increases in the concentration of IL-15 did not further 
enhance the proliferative response of CD56b~ig  ht NK ceils. In 
data not shown, the median effective concentration (ECs0) 
for IL-15 in these CD56b'~g  h~ NK proliferation  experiments 
ranged between 3.0 and 7.0 ng/ml (i.e., *0.2 and 0.5 nM), 
whereas the ECs0 in identical experiments with IL-2 ranged 
between 0.45  and 0.7 ng/ml (i.e., "~30 and 50 pM). 
The vast majority of CD56  ~m NK cells constitutively ex- 
press the intermediate affinity IL-2R (4), and exhibit min- 
imal proliferation in the presence of saturating concentrations 
of IL-2 (2). As shown in Fig. 1 B, incubation of CD56  ~m 
NK cells in increasing concentrations of either IL-2 or IL-15 
produced very little proliferation  relative to the CD56b~ig  ht 
NK cells (Fig.  1 A). 
We next examined the effects of anti-IL-2Ro~ and anti- 
IL-2RB mAbs on IL-2- and IL-15-induced proliferation in 
CD56bns  h' NK cells. Preincubation of CD56b~ig  h~ NK cells 
with anti-IL-2Rc~ resulted in significant inhibition of IL-2- 
induced proliferation at concentrations of IL-2 that selectively 
saturate the high affinity IL-2 receptor (Fig. 1 C) (2, 3). In 
contrast, anti-IL-2Rol had no effect  on IL-15-indueed prolif~- 
ation of CD56bng  ht NK cells (Fig. 1 D). Anti-IL-2Rfl mAb 
inhibited IL-2-induced proliferation  of CD56  b~ght NK cells 
at low concentrations  of IL-2 (0.1-10 ng/ml), but could be 
overcome at higher concentrations  of IL-2 (Fig. 1 E). Anti- 
IL-2RB mAb could also inhibit IL-15-induced proliferation 
of CD56~s  ht NK cells at 10 ng/ml, but this could be over- 
come at lO-fold higher concentrations of IL-15 (Fig. 1 F). 
Thus,  whereas  IL-2 interacts  with both  the IL-2Rc~ and 
IL-2RB components of the IL-2R to induce a proliferative 
response in CD56b~ig  ht NK cells, IL-15 appears to bind to 
IL-2RB but not IL-2Ret in producing a similar functional 
response, as shown in other systems (5, 6). 
As shown in Fig. 1 A, an increase in IL-15 concentration 
from 1 to  10 ng/ml results in CD56bng  ht NK cells going 
from no proliferative response to a maximum proliferative 
response, respectively. At concentrations  of IL-15 between 
I and 10 ng/ml (i.e., ,v2 ng/ml), a submaximal proliferative 
response is noted (Fig. 2). It is important to note that the 
same proliferative response is produced with IL-2 at approxi- 
mately lO-fold lower concentrations (i.e., '~0.15 ng/ml of 
IL-2). Submaximal concentrations of IL-15 can combine with 
low concentrations  of IL-2 to produce an additive prolifera- 
tive response to CD56bng  h~ NK cells, but only before full 
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Figure  2.  A suboptimal concentration of IL-15 potentiates  prolifera- 
tion of CD56b'is  ht NK cells cultured in suboptimal concentrations of IL,2. 
Sorted CD56bfig  ht NK ceils were cultured in medium plus increasing con- 
centrations IL-2 in the presence or absence of 2 ng/ml of IL-15 for 84 h 
and then assayed for methyl-[3H]thymidine incorporation. Once IL-2 fully 
saturates the high aflqnity  Ib2R (15 ng/ml), the potentiating  effect of IL-15 
is lost. Results represent the mean  _+  SE of triplicate wells. 
saturation of the high affinity IL-2R with IL-2, which occurs 
at 15 ng/ml of IL-2. At that point, the two cytokines are 
no longer additive (Fig. 2). Furthermore, when IL-15 induced 
a maximal proliferative response of the CD56b~ig  h' NK cells 
at 10 ng/ml, combinations with lower concentrations of IL-2 
which only saturate the high affinity IL-2R, did not further 
augment proliferation  (data not shown). 
Activation of NK Cytotoxic Activity with IL-15.  NK cells 
display LAK activity against NK-resistant  target cells after 
incubation in concentrations  of IL-2 that saturate the inter- 
mediate  affinity  IL-2  receptor  (2).  This  activity can  be 
abrogated in the presence of anti-IL-2RB mAb (13). Incuba- 
tion of CD56  a~n NK cells in the presence of IL-15 resulted 
in LAK activity against the NK-resistant cell line COLO 205 
in  a dose-dependent  fashion  (Fig.  3 A).  The IL-2  dose- 
response curve was identical to that of IL-15 (data not shown). 
Like  IL-2,  IL-15-induced LAK  activity was  completely 
abrogated in the presence of anti-IL-2RB  mAb (Fig. 3 B). 
Thus IL-15 binds to IL-2P,~ to enhance cytotoxic activity 
of human NK cells. A similar dose-response curve was ob- 
tained when NK cells were incubated with increasing con- 
centrations of IL-15 and assayed  for ADCC against the P815 
murine mastocytoma cell line in the presence of a rabbit 
anti-mouse antiserum (Fig. 3 C). 
IL-12 is known to induce LAK activity in human NK cells, 
and coincubation of NK ceils with both IL-12 and IL-2 can 
have an additive effect on NK cytotoxic activity (14, 15). As 
can be seen in Fig. 3 D, combinations  of IL-12 and IL-15 
resulted in additive LAK activity that was nearly identical 
to that seen with IL-12 and IL-2. However, there was no 
synergistic or even additive effect on LAK activity when NK 
calls were incubated with equivalent amounts of IL-2 and 
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Figure 3.  IL-15  induces LAK activity in CD56  dim NK cells. (A) Purified CD56  d~m NK cells were incubated at increasing concentrations of IL-15 
for 18 h and then tested against COLO 205 target cells in a standard 4-hour Cr-rdease assay. E/T ratio was 5:1. Results represent the mean +  SE 
of triplicate wells. (B) IL-15-induced  LAK activity of CD56  aim NK cells is abrogated by an anti-IL-2RB mAb. CD56  alto NK cells were cultured in 
medium alone ([]), medium supplemented with isotype control mAb and I ng/ml IL-15 (ll), or medium supplemented with anti-IL-2RB mAb and 
1 ng/ml IL15 (O). E:T ratios of 2.5:1, 5:1, and 10:1 were used against COLO 205 target cells. (C) [L-15 potentiates NK cell ADCC. Purified CD56  ~ 
NK cells were incubated at increasing concentrations of IL,15 and then assayed for ADCC against the P815 cell line in the presence or absence of 
goat anti-mouse lymphocyte polysera. Specific ADCC was calculated by subtracting the percent lysis of noncoated targets from that of targets coated 
with polysera. Results represent the mean _+ SE of triplicate wells. (D) I1.,15 or IL.2 synergize  with IL-12  to enhance the cytotc~ic activity of CD56  ~ 
NK cells. CD56  am NK cells were incubated in 1 ng/ml IL-2, 1 rig/m1 LL-15, 10 U/ml ID12, alone or in combination, for 24 h and then tested for 
cytotoxicity against COLO 205 target cells at an E/T ratio of 5:1. Results represent the mean  +  SE of triplicate wells. 
IL-15.  Consistent  with  this,  incubation  with  IL-2, IL-15, 
and IL-12 did not enhance NK cytotoxic activity any more 
than the combination of IL-2 with 1L-12 or IL-15 with IL-12. 
NK  Cell  Cytokine  Production in  Response to  11..-I5.  A 
number of studies have shown that activation of human NK 
cells with IL-2, IL-12, or TNF-ol can result in cytokine produc- 
tion by human NK cells (16-18). We assayed for the produc- 
tion of IFN-3,, TNF-oL, and GM-CSF, by NK cells after ac- 
tivation by IL-15. Highly purified populations of NK cells 
were sorted from fresh blood and cuhured for 72 h with IL-2 
and IL-15 alone or in combination with TNF-c~ or IL-12. 
As shown in Fig. 4 A, IFN-3' production by NK calls was 
negligible in the presence of TNF-c~, IL-12, IL-15, or IL-2. 
The combination of IL-2 plus IL-15 did not result in significant 
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Figure  4.  Ib15 and IL-2 stimuhte CD56  dim NK cell cytokine produc- 
tion in a similar fashion. 10  s sorted CD56  dlm NK cens (>97% pure) were 
plated in U-bottom wells in 200 #1 of medium supplemented with one 
or more of the following cytokines: TNF-~, (300 U/ml), IL-12  (10 U/ml), 
I1.,2 (10 ng/ml), or IL-15 (10 ng/ml). Cells were incubated  for 72 h at 
which time the culture  supernatants were harvested and assayed for the 
presence of either IFN-3, (A), TNF-~ (B), or GM-CSF (C), using an ELISA. 
Cytokine production is measured in pg per m]. 
IFN-3' production. When IL-12 was combined with either 
IL-2 or IL-15,  significant  and nearly equivalent  amounts of 
INF-'), were produced. The same was true of TNF-ol produc- 
tion by NK cells  (Fig.  4 B).  However, in repeated experi- 
ments, the production of GM-CSF by IL-2-stimulated NK 
cells was nearly twice that of IL-15-stimulated NK cells. It 
is important to note that there was no additive production 
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Figure  5.  Ib15 binds to receptors on human NK cells. Scatchard anal- 
ysis of lzsI-I~15 (A) and t2sI-IL-2  (B) binding to NK-em'iched resting PBL. 
Equilibrium  binding conditions were as described by Girl et al. (6). 
of GM-CSF when NK cells were incubated with both IL-2 
and IL-15 (Fig. 4 C), again emphasizing the redundant na- 
ture of these two ligands.  Both IL-15 and IL-2 synergized 
with TNF-o~ or IL-12 in inducing NK production of GM- 
CSF, but there appeared to be slightly greater production 
of GM-CSF when IL-2 was used in these combinations, as 
compared  to IL-15. 
Binding  of Radiolabeled  IL-2  and  11..-I5 to  Human  NK 
Cells.  The results from the proliferation,  cytotoxicity, and 
cytokine production assays strongly suggested that IL-2 and 
IL-15 were sharing components of the IL-2R on NK ceUs 
for binding and signal transduction.  To investigate  this fur- 
ther, radiohbeled IL-2 and IL-15 were used to perform binding 
inhibition assays on human CD56 ai~ NK cells that express 
the intermediate affinity IL-2RB3'.  In repeated experiments, 
incubation of highly purified  (>97%)  CD56 ai~ NK  ceUs 
with  t2sI-IL-2  and  a  100-fold  excess  of unlabeled  IL-15 
resulted in 85-95% inhibition of tzsI-IL-2 binding compared 
to control (100-fold excess of unlabded IL-2).  Likewise,  in- 
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IL-2 resulted in 85-95%  inhibition of nq-IL-15  binding 
compared to control. Incubation with anti-IL-2RB resulted 
in a similar (>90%) inhibition of binding of both radiola- 
beled IL-2 and IL-15 (data not shown). Together, these results 
support the notion that IL-2 and IL-15 share common  binding 
sites on CD56  dim NK cells. Sufficient numbers of cells could 
not be obtained to perform this assay on  CD56 brisht  NK 
cells. 
To better quantitate the affinity of the NK cell for both 
IL-15 and IL-2, we performed a series of Scatchard analyses 
of 12q-IL-15 binding to NK-enriched (75-90%  by FACS  | 
analysis) resting PBL, and of nsI-IL-2 binding to the same 
population. The analysis of one experiment for IL-15 is shown 
in Fig. 5 A  and indicates  that IL-15 binding sites include a 
low number of high affinity receptors (KD1 =  11.7 pM, 45 
R1 sites), and approximately 189 lower affinity P,2 sites (Kin 
=  500 pM). Analysis of IL-2 binding in the same experi- 
ment showed the presence of high afffinity IL-2K (KDI  = 
55 pM,  100 K~ sites) and a larger number of intermediate 
affinity  IL-2K (Kin  =  1.8 nM,  1110 R2 sites,  Fig.  5 B). 
Consistent with this, FACS  ~ analysis showed the majority 
of NK cells expressing IL-2R~ and ",,10%  of the NK cells 
expressing IL-2Rc~, a component of the high affinity but not 
the intermediate affinity 1L-2R (19). Approximately 10% of 
the cells were  CD56bri# t.  In another experiment in which 
more than 90% of the cells were CD3-CD56 + by FACS  | 
analysis, a similar binding pattern for iodinated IL-15 was 
detected (data  not shown). 
Discussion 
The recent discovery and characterization of IL-15 has resulted 
in the identification of a novel ligand that uses components 
of the IL-2R (5, 6). Using cell lines transfected with the human 
IL-21~ and IL-2R3' protein subunits, Girl et al.  (6) have 
demonstrated that both subunits are required for 1I.-15 binding 
and signal transduction. The a  subunit of the IL-2K is not 
involved in IL-15 binding (5, 6). The vast majority of human 
NK cells found in unstimulated peripheral blood constitu- 
tively express functional forms of the IL-2R, yet neither resting 
or activated NK cells produce IL-2 (1). As IL-15 appears to 
be abundantly and constitutively expressed in a variety of 
tissues, including activated monocytes/macrophages (5), this 
cytokine may have an important role in the regulation of NK 
cell function. We have therefore examined the effects of IL- 
15 on functionally distinct subsets  of human NK cells. 
The vast majority of CD56  ~  NK cells express only the 
intermediate affinity heterodimeric IL-2I~% and display a 
weak proliferative but strong cytotoxic response to IL-2 (2, 
4).  Both  the  proliferative  and  cytotoxic  responses  of 
CD56  '~m NK  cells  to  IL-15  were indistinguishable from 
those of IL-2 at equivalent concentrations. Likewise, IL-15- 
induced NK cell cytokine production was strikingly similar 
to that seen with IL-2, with the possible exception of GM- 
CSF production. Functional responses of the CD56  a~m NK 
cells to IL-15 could be abrogated in the presence of antibodies 
directed against IL-2R~, indicating that IL-15 was binding 
to this component of the intermediate affinity IL-2R. Studies 
performed with radiolabeled  IL-2 and IL-15 and increasing 
concentrations ofunlabded IL-2 or IL-15 suggested that these 
two cytokines share common binding sites on CD56  dim NK 
cells (Carson, W.E., and M.A. Caligiuri, unpublished ob- 
servations).  Work by Giri et al. (6) suggests that IL-15, like 
IL-2 (20), also uses the 3' subunit of IL-2R for binding and 
signaling.  Studies to definitively address this in human NK 
cells must await the development of a mAb directed against 
the IL-2K3' subunit. 
It is important to note that whereas combinations of IL- 
15  or  IL-2  could synergize equally  well  with  IL-12  on 
CD56  ~m NK cells, illustrating the NK cell's potential to 
markedly increase cytotoxicity and cytokine production, the 
combination of IL-15 with IL-2 never produced an additive 
or synergistic response, but exhibited the same stimulation 
as either cytokine acting alone. This would imply that for 
these functions on human CD56  d~ NK calls, IL-15 and IL-2 
are mutually redundant (21). However, the relative abundance 
of these two cytokines may lend some insight into which 
combination with IL-12 is likely to be more relevant in vivo. 
T cells transiently produce IL-2 after antigen activation, and 
require this cytokine in order to mount a successful immune 
response (22). As no other effector cell of the immune system 
is known to produce IL-2, its availability for NK cell activa- 
tion via the intermediate affinity IL-2R is likely to be quite 
limited. In contrast, IL-12 production by activated  mono- 
cytes/macrophages has been shown to be a critical  compo- 
nent of host defense against invading pathogens via its stim- 
ulation of NK cell IFN-3' production (for a review see reference 
23). As IL-15 is also produced by activated monocytes/mac- 
rophages (5),  and can synergize with IL-12 in stimulating 
NK cell IFN-3" production, IL-15 may be the more impor- 
tant ligand for the intermediate affinity IL-2R expressed on 
human NK cells. The definitive experiments to test this hy- 
pothesis await the in vivo administration of neutralizing an- 
tibodies directed against IL-15 in animal models. Likewise, 
it remains to be determined if NK cells themselves can pro- 
duce IL-15. 
The CD56  brlght NK  cells constitutively express both a 
high affinity and intermediate affinity IL-2K, and in contrast 
to CD56  d~ NK cells, the proliferative responses to IL-2 and 
IL-15 were distinct. At concentrations of 0.10 and 1.0 ng/ml 
of IL-2, a progressive increase in DNA synthesis was noted 
among the CD56  bqht NK cells, whereas IL-15 showed no 
evidence of activity at identical concentrations.  Previous work 
(2, 24) has shown that these concentrations of IL-2 result 
in partial to complete saturation of the heterotrimeric high 
affinity IL-2RaB3", supported in the present study by the 
partial inhibition seen in the presence of anti-IL-2Kcr  mAb. 
A 10-fold higher concentration of IL-2 (10 ng/ml) partially 
saturates  the intermediate affinity IL-2R but also provides 
continual complete saturation of the high affinity IL-2R for 
the entire period of culture. The latter effect is likely to be 
responsible for the maximum proliferation noted at this point, 
as further saturation of the intermediate affinity IL-2K with 
1401  Carson et al. even higher concentrations of IL-2 does not enhance prolifer- 
ation (2). 
In distinct contrast to 11,-2, the first CD56bng  ht NK pro- 
liferative response to IL-15 did not occur until log increases 
in concentration reached 10 ng/ml. Anti-IL-2ILo~ mAb did 
not inhibit this response, whereas anti-IL-2Pq8 did. The ex- 
planation for the 10-fold difference between the IL-2 and IL-15 
dose-response curves for CD56b~g  h' NK cell proliferation is 
not clear at this time, but similar differences have been noted 
for PHA-activated human T  cells (5).  Scatchard analysis of 
radiolabeled IL-2 and IL-15 binding to unstimulated human 
NK cells showed that both cytokines identified high and in- 
termediate aflL,  fity receptor sites. The high af~nity IL-2R sites 
were few in number and are likely to represent those expressed 
by the CD56b~i# '  NK  subset  (1%  of PBL,  10%  of NK 
cells), which is the only cell known to constitutively express 
high affinity IL-2R in unstimulated PBL (2, 3). The func- 
tional significance of NK cell receptors that bind IL-15 with 
apparent high aflfinity (K~I of 11.7 pM)  and lower aflfinity 
(KD2 of 500 pM) as shown in Fig. 5 cannot be determined 
at this time, as radiolabeled ligand binding assays were per- 
formed at 4~  whereas biologic responses were assayed at 
37~  It is possible  that IL-15 uses other receptor compo- 
nents not required for IL-2. Indeed, Grabstein et al. (5) and 
Girl et al. (6) have identified murine cell lines that proliferate 
vigorously in response to IL-2, but poorly or not at all to IL-15. 
In summary, we have characterized the functional responses 
of human NK cell subsets to IL-15. IL-15 appears to use com- 
ponents of the IL-2R to induce proliferation, cytotoxic ac- 
tivity, and cytokine production in this subset of lymphocytes. 
Whereas IL-15 was found to share many biologic properties 
of IL-2 in this regard, certain properties of IL-15 were dis- 
tinct from IL-2 in CD56b~ h' NK cells.  In animal models, 
monocyte/macrophage-derived cytokines have been shown 
to be important in defense against invading pathogens via 
their regulation of NK cell IFN-'y production (20). Whereas 
we and others (25) have shown that IL-2 can potentiate these 
functions in vitro, the limited production of IL-2 by acti- 
vated T  cell subsets might suggest that this mechanism is 
not operative in vivo. In distinct contrast to IL-2, IL-15 ap- 
pears to be abundantly expressed in a variety of tissues  and 
cell types, including activated monocytes/macrophages (5). 
The constitutive expression of functional IL-2 receptors on 
human NK cells, and our in vitro demonstration that IL-15 
can potentiate NK cell cytokine production and cytotoxic 
activity in combination with other monocyte/macrophage- 
derived cytokines suggests  that  this  synergy may also  be 
important in vivo. Additional studies with IL-15 should pro- 
vide further insight into the role of this molecule in normal 
host immunity. 
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